tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OKYO Stock Latest News

OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
Company AnnouncementsOKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
3d ago
6K
OKYO
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
PremiumCompany Announcements
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
3d ago
6K
OKYO
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
PremiumThe Fly
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
3d ago
OKYO
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
PremiumCompany Announcements
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
3d ago
6K
OKYO
Okyo Pharma announces ordinary shares offering, no amount given
PremiumThe Fly
Okyo Pharma announces ordinary shares offering, no amount given
3d ago
OKYO
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
PremiumCompany AnnouncementsOKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
5d ago
6K
OKYO
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
Premium
Company Announcements
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
5d ago
6K
OKYO
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program
Premium
Company Announcements
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program
6d ago
6K
OKYO
Okyo Pharma appoints Mantelli as Chief Medical Officer
PremiumThe Fly
Okyo Pharma appoints Mantelli as Chief Medical Officer
6d ago
OKYO
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial
PremiumCompany Announcements
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial
16d ago
6K
OKYO
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting
PremiumCompany Announcements
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting
17d ago
6K
OKYO
OKYO Pharma Wins FDA Backing on Phase 2b/3 Design for Urcosimod in Neuropathic Corneal Pain
PremiumCompany Announcements
OKYO Pharma Wins FDA Backing on Phase 2b/3 Design for Urcosimod in Neuropathic Corneal Pain
19d ago
6K
OKYO
Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod
PremiumThe FlyOkyo Pharma announces highlights from Type C meeting with FDA on urcosimod
19d ago
OKYO
OKYO Pharma Wins FDA Compassionate-Use Clearance for Urcosimod in Severe Neuropathic Corneal Pain
Premium
Company Announcements
OKYO Pharma Wins FDA Compassionate-Use Clearance for Urcosimod in Severe Neuropathic Corneal Pain
24d ago
6K
OKYO
Okyo announces FDA authorized single-patient expanded IND for urcosimod
Premium
The Fly
Okyo announces FDA authorized single-patient expanded IND for urcosimod
24d ago
OKYO
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential
PremiumRatings
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential
1M ago
OKYO
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase
PremiumCompany Announcements
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase
1M ago
6K
OKYO
Okyo Pharma appoints Robery Dempsey as CEO
PremiumThe Fly
Okyo Pharma appoints Robery Dempsey as CEO
1M ago
OKYO
OKYO Pharma Rings Nasdaq Opening Bell as Urcosimod Advances After Positive Phase 2 NCP Data
PremiumCompany Announcements
OKYO Pharma Rings Nasdaq Opening Bell as Urcosimod Advances After Positive Phase 2 NCP Data
2M ago
6K
OKYO
OKYO Pharma Chairman Increases Stake Amid Promising Drug Trials
PremiumCompany AnnouncementsOKYO Pharma Chairman Increases Stake Amid Promising Drug Trials
2M ago
6K
OKYO
Okyo Pharma chairman acquires 24,551 company shares
Premium
The Fly
Okyo Pharma chairman acquires 24,551 company shares
2M ago
OKYO
OKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain
Premium
Company Announcements
OKYO Pharma Reports Positive Phase 2 Results for Urcosimod in Neuropathic Corneal Pain
2M ago
6K
OKYO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >